REVOLUTIONIZING
the Treatment of Advanced Parkinson’s Disease
Intrance Medical Systems, Inc., a subsidiary of Sweden-based Intrance Holdings AB, is a private biopharmaceutical company focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinson’s disease in the U.S., Canada, Mexico, South America, Japan and Taiwan. Intrance’s lead product, known as Lecigon® in Europe, is a fixed-dose combination treatment of carbidopa, entacapone, and levodopa for enteral infusion in advanced Parkinson’s disease patients. The product has been commercially launched in the Nordic countries and select European territories where it is gaining market share and user acceptance. The company is planning to advance its U.S. clinical development program in this target indication and has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).
Our History
We have a successful global history supported by a strong scientific foundation and proven clinical and commercial expertise.
Our Approach
Intrance’s novel approach has the potential to become a new standard of care allowing for continuous use and optimized treatment for late-stage disease.
Parkinson's Disease
Parkinson's disease (PD) affects nearly one million people in the United States. Most people living with PD will eventually progress to the advanced stage (APD).